Physician profile
Shawnda R Pointer
NPI 1689104143
$3,428.63
in general payments reported to CMS, 2019-2025
24 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what 88% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $359 · 2022: $233 · 2023: $1,077 · 2024: $529 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037 · Travel and Lodging: $700 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.43 |
| Travel and Lodging | $700.16 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,982.94 | 2021-2025 | Intellis Adaptivestim, Synchromedii |
| Boston Scientific Corporation | $185.60 | 2021-2025 | Intracept |
| Abbvie INC. | $185.37 | 2021-2023 | |
| Abbott Laboratories | $150.52 | 2023-2025 | Eterna, Proclaim |
| Nalu Medical, INC. | $136.92 | 2022 | |
| Averitas Pharma INC. | $120.50 | 2025 | Qutenza |
| Azurity Pharmaceuticals, INC. | $108.68 | 2024-2025 | Horizant |
| Collegium Pharmaceutical, INC. | $95.55 | 2021-2025 | Belbuca, Xtampza |
| Arbor Pharmaceuticals, INC. | $59.54 | 2021 | |
| Lilly USA, LLC | $43.90 | 2021 | |
| Almatica Pharma LLC | $43.84 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $38.37 | 2025 | |
| Si-Bone, INC. | $35.37 | 2024-2025 | |
| Saluda Medical Americas, INC. | $31.51 | 2024 | Evoke |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.25 | 2025 | Relistor |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $25.58 | 2022 | |
| Pfizer INC. | $25.02 | 2021 | |
| Protega Pharmaceutials INC | $22.36 | 2023 | Roxybond |
| Biotronik Nro, INC. | $21.63 | 2025 | Prospera |
| Biohaven Pharmaceutical Holding Company LTD. | $20.28 | 2022 | |
| Mml US, INC. | $20.27 | 2023 | Reactiv8 |
| Tonix Medicines, INC. | $18.37 | 2025 | Tonmya |
| Spinal Simplicity, LLC | $14.71 | 2025 | Ha Minuteman G3-R |
| Biohaven Pharmaceuticals, INC. | $12.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shawnda Pointer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.